| Title |
Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives
|
|---|---|
| Published in |
American Journal of Clinical Dermatology, November 2017
|
| DOI | 10.1007/s40257-017-0325-6 |
| Pubmed ID | |
| Authors |
Elisa A. Rozeman, Tim J. A. Dekker, John B. A. G. Haanen, Christian U. Blank |
| Abstract |
Malignant melanoma accounts for the highest number of deaths from skin cancer, and the prognosis of patients with stage IV disease has historically been poor. Novel insights into both mutations driving tumorigenesis and immune escape mechanisms of these tumors have led to effective treatment options that have revolutionized the treatment of this disease. Targeting the MAPK kinase pathway (with BRAF and MEK inhibitors), as well as targeting checkpoints, such as cytotoxic T-lymphocyte associated protein 4 (CTLA-4) or programmed death 1 (PD-1), have improved overall survival in patients with late-stage melanoma, and biomarker research for personalized therapy is ongoing for each of these treatment modalities. In this review, we will discuss current first-line treatment options, discuss biomarkers supporting treatment decisions, and give an outlook on (combination) therapies we expect to become relevant in the near future. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 101 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 101 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 17 | 17% |
| Student > Ph. D. Student | 15 | 15% |
| Student > Bachelor | 12 | 12% |
| Researcher | 10 | 10% |
| Student > Doctoral Student | 8 | 8% |
| Other | 16 | 16% |
| Unknown | 23 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 21 | 21% |
| Medicine and Dentistry | 21 | 21% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 7% |
| Agricultural and Biological Sciences | 6 | 6% |
| Immunology and Microbiology | 5 | 5% |
| Other | 9 | 9% |
| Unknown | 32 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 June 2018.
All research outputs
#14,964,325
of 23,016,919 outputs
Outputs from American Journal of Clinical Dermatology
#713
of 986 outputs
Outputs of similar age
#251,041
of 437,754 outputs
Outputs of similar age from American Journal of Clinical Dermatology
#10
of 14 outputs
Altmetric has tracked 23,016,919 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 986 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.9. This one is in the 23rd percentile – i.e., 23% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 437,754 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.